Last reviewed · How we verify
Hydrofol — Competitive Intelligence Brief
unknown
docosanoic acid
Peroxisome proliferator-activated receptor delta, Peroxisome proliferator-activated receptor alpha, Peroxisome proliferator-activated receptor gamma
Metabolic
Live · refreshed every 30 min
Target snapshot
Hydrofol (docosanoic acid). Hydrofol works by activating the peroxisome proliferator-activated receptor alpha (PPAR-alpha), a protein that regulates the expression of genes involved in lipid metabolism.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Hydrofol TARGET | docosanoic acid | unknown | docosanoic acid | Peroxisome proliferator-activated receptor delta, Peroxisome proliferator-activated receptor alpha, Peroxisome proliferator-activated receptor gamma |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (docosanoic acid class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Hydrofol CI watch — RSS
- Hydrofol CI watch — Atom
- Hydrofol CI watch — JSON
- Hydrofol alone — RSS
- Whole docosanoic acid class — RSS
Cite this brief
Drug Landscape (2026). Hydrofol — Competitive Intelligence Brief. https://druglandscape.com/ci/docosanoic-acid. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing